Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and
Glen S Hazlewood1, Claudia Metzler2, George A Tomlinson3
1Department of Internal Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, T2N1N1 Canada.
Objective:
To determine the comparative efficacy of non-biologic treatments for remission maintenance in ANCA-associated vasculitis.
Methods:
We identified all randomized trials comparing leflunomide, azathioprine, methotrexate or mycophenolate mofetil in adult patients with granulomatosis with polyangiitis or microscopic polyangiitis. Relapse-free survival was compared through hazard ratios (HR) using a Bayesian fixed-effects network meta-analysis. Multiple sensitivity analyses were performed to explore biases identified in one trial using original trial data.
Results:
Three trials were available (leflunomide-methotrexate, methotrexate- azathioprine, azathioprine-mycophenolate). Mycophenolate was inferior to all treatments, although the 95% credible interval (CrI) of the HR relative to methotrexate crossed 1. Leflunomide was superior to azathioprine (HR 0.43 [95% CrI: 0.14-1.3]) and methotrexate (HR 0.47 [95% CrI: 0.18-1.2]), although the 95% CrI also crossed 1. There was a 90% probability that leflunomide was the best treatment. After down weighting the effect of leflunomide vs. methotrexate for early trial termination and slow MTX dose escalation, there remained a 55% probability leflunomide was best.
Conclusion:
Based on indirect evidence, leflunomide is effective in maintaining remission in granulomatosis with polyangiitis or microscopic polyangiitis relative to other non-biologic treatments. Further randomized trials of leflunomide are needed for confirmation.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Atherosclerosis III: Management

